Material and methods Thirty seven consecutive outpatients who had received warfarin for not less than three months were studied. There were 20 women aged 28-73 years (mean 60 years) and 17 men aged 28-78 years (mean 59 years). Eleven had been receiving warfarin for less than one year, while eight had been treated for longer than 10 years. The average dose was 4 5 mg warfarin per day with wide variation between 1 and 9-5 mg per day. Eighteen patients had valvular heart disease (often with prostheses), 10 arterial thrombosis (stroke, myocardial infarction, peripheral vascular disease), and nine had recurrent venous thrombosis or pulmonary embolus, or both.
The doses of warfarin used for anticoagulation are monitored in most clinics by prothrombin time tests.
Such an approach is well tested, and although the thromboplastins used in the prothrombin time test may vary from laboratory to laboratory, the introduction of international standards and national quality control schemes has led to considerable confidence in the performance of prothrombin time tests. Little interest has been shown in recent years as to how concentrations of the different vitamin K dependent factors in patients anticoagulated with warfarin may affect the prothrombin time test. This is, we suspect, because popular belief presupposes that coagulation factors are equally depressed in patients stabilised on long term oral anticoagulant treatment. This study questions such conventional wisdom and explores the sensitivity of the prothrombin time test, using Manchester human brain comparative thromboplastin to the differing values of the vitamin K dependent factors II, VII, IX and X. Since this study was performed and submitted for publication human brain thromboplastins have been withdrawn because of fears of possible viral contamination. Our findings, however, remain of interest, raising as they do important questions as to what is happening to coagulation factors in the long term orally anticoagulated patient and how such treatment should be monitored.
Accepted for publication 30 June 1986 Material and methods Thirty seven consecutive outpatients who had received warfarin for not less than three months were studied. There were 20 women aged 28-73 years (mean 60 years) and 17 men aged 28-78 years (mean 59 years). Eleven had been receiving warfarin for less than one year, while eight had been treated for longer than 10 years. The average dose was 4 5 mg warfarin per day with wide variation between 1 and 9-5 mg per day. Eighteen patients had valvular heart disease (often with prostheses), 10 Because of the considerable differences in the absolute values of the factors found in these anticoagulated patients, it is impossible to determine from this equation the relative sensitivity of the BCR Factors II, VII, IX and X concentrations in patients receiving long term warfarin 97 around 15-20% of normal. Inspection of his original work,6 7 however, lends scant support for such a view in patients receiving warfarin as anticoagulant. By way of contrast, Winter and Douglas8 contend that individual factor values are not depressed to the same extent during anticoagulant treatment, an opinion based on the findings of Owen et al9 and amply confirmed in this study: factor X shows the greatest depression, factor IX the least, with factors II and VII at intermediate levels.
In recent years interest has been shown in the control of oral anticoagulant treatment with individual factor assays exploiting chromogenic amidolytic peptide substrate technology.9 1 Presumably, the original rationale for such an approach was based on what we believe is the mistaken view-that is, if all vitamin K dependent factors fall to about the same values in patients taking warfarin long term then any one of the factors can be chosen and assayed for control of anticoagulant treatment. We suggest that the reason single factor assay may be appropriate for such control is connected with finding similar variations in the parameters of the intensity of anticoagulant treatment studied in these 37 adequately anticoagulated patients. Thus, although the range of the parameters was different (BCR 1.5-4.8, factor II 7-54%, factor VII 18-80%, factor IX 23-76%, factor X 7-28%), their coefficients of variation were very similar [23, 31, 31, 27, 31%, respectively]. Thus we suggest that these parameters may, in practice, be interchangeable as measures of intensity of anticoagulant control, as long as the relevant ranges are properly established and verified clinically.
Owren`2 observed succinctly that, "the goal of anticoagulant therapy is to prevent thrombosis but to preserve haemostasis." Although clinical observation encourages the use and safety of warfarin and other coumarins for satisfactory anticoagulation, the rationale for their use remains uncertain, as does explanation of the occasional unexpected episodes of bleeding that occur despite good control of warfarin anticoagulation with prothrombin time tests. It may not be fortuitous that the different anticoagulants heparin and warfarin exert major effects on factor X activity and concentration. With regard to the importance of preserving haemostasis in patients receiving warfarin long term, we found that both the values of factors X and II in some patients approached the critical levels of vitamin K dependent factors below which haemostasis is jeopardised (factor X 8%,`3 factor II 9%.12
This study set out to investigate the sensitivity to the different vitamin K dependent factors found in patients taking long term anticoagulants of the measure of anticoagulant control most widely used in Britain at the time (the prothrombin time test expressed as British corrected ratio, or BCR using Manchester human brain thromboplastin). Because this product has been withdrawn, detailed discussion of the multivariate regression analysis of BCR and factors II, VII, IX and X and the subsequent analysis of variance will not be pursued, as our concern about what the prothrombin time test actually measures will have to be repeated with the animal thromboplastins in current use. Nevertheless, certain findings are worth mentioning. The prothrombin time test is generally considered to be the most sensitive to changes in factor VII and to a lesser extent factor X, but the prothrombin time test is thought to be relatively insensitive to factor I1.14 In this study factor II accounted for 91 % of the explained variance of BCR, factor VII 7%, and factor X only 0.4%. The known sensitivities of human brain thromboplastin to factor VII and X deficiencies, when such states occur in isolation,15 would seem irrelevant to the changes occurring in the interrelated vitamin K dependent coagulation factors in patients receiving long term warfarin. Whether the other thromboplastins show similar results is awaited with interest. It will be particularly important to determine whether other prothrombin time tests are sensitive to the low values of factors II and X occurring with warfarin long term because of the critically low values of these factors found in some patients stabilised on long term oral anticoagulant treatment. Thus we note with concern that one of our patients who had been receiving warfarin for 17 years was found to have a BCR of 1-6, factor X of only 12%, while her factor II was 48%, factor VII 70%, and factor IX 66%.
